Kornimate/medical-research-clean huggingface dataset:
study of professional and individual factors of covi-19 and impact on return to work

Conditions: COVID-19

Summary: started on january 9, 2020 with the announcement of the discovery of a new sars-cov-2 coronavirus, the covid-19 pandemic is responsible as of june 21, 2020 for 160,377 confirmed cases in france, 29,640 deaths and 9,823 hospitalizations. the grand est region is one of the regions in france that was most precociously and strongly affected by the epidemic, in particular the strasbourg university hospital. faced with the heavy use of the healthcare system, hospital staff of all categories are an essential resource to be preserved. several studies have shown the significant impact of covid-19 on doctors and caregivers. in order to better protect these personnel and avoid contamination that could be harmful to their health but also because of the consequences in terms of staff, it is necessary to better understand the risk factors for transmission of this infection, the means of protection, the evolution of the disease and the determinants of the return to work. few studies have explored on such a large workforce and in detail the professional risk factors for developing covid-19 within different groups of hospital professionals including also non-caregivers and the evolution when returning to work in an outpatient population.


Eligibility criteria:
inclusion criteria: * major subject (≥18 years old) * professionals from the university hospitals of strasbourg (hus) * professionals who had been working at the hus at the time of the diagnosis of sars cov-2 infection. * subject having not expressed, after being informed, opposition to the reuse of their data for research purposes exclusion criteria: - subject who expressed their opposition to participating in the study

Keywords: covid-19 sars-cov-2
f-cast for individuals with substance use disorder

Conditions: Substance Use Disorders

Summary: examining the effectiveness of the f-cast based on a controlled randomized trial in patients with sud residing in a therapeutic community.

background and aims: substance use disorder (sud), an urgent public health concern, is a chronic relapsing brain disorder caused by psychoactive substances, characterized by cognitive, behavioral, and physiological symptoms, severely impacting every life domain. repeated substance use leads to impairments in higher cognitive abilities, termed executive functions (ef), and leads to sud chronicity. furthermore, ef deficits are associated with difficulties in sensory processing, severely limiting daily functions and with reported high incidence in sud. however, to date both are not addressed therapeutically. this translational study aims to enhance rehabilitation success in patients with sud residing in a therapeutic community (tc) by employing sensory and ef strategies utilizing the functional cognitive and sensory treatment (f-cast), an innovative personalized therapy. methods: a qualitative study will be nested in a single-blind, controlled randomized trial, comparing two groups: (i) experimental group- f-cast - in which therapy is individually tailored for successful task performance and where the focus is on strategies for improving sensory and ef deficits and (ii) control group - standard care - the typical treatment given in the therapeutic community. measurement will be conducted by assessors blind to group allocation at 4 time points: t1- pre-intervention; t2- post-intervention; t3- at a 1-month follow-up; and t4- at a 3-month follow-up. population: forty-eight adults diagnosed with sud, aged 18-45 years, with no significant cognitive deficits, and residing in a tc for sud. tools: both objective and subjective measures to evaluate tc performance will be applied. additionally, interviews will be conducted to provide a deeper understanding of the perceived performance and difficulties. expected results: f-cast will lead to improved rehabilitation success and treatment duration, better compliance with tc requirements, and greater satisfaction, compared to control group.

Eligibility criteria:
inclusion criteria: * diagnosed by a psychiatrist and meeting the dsm-v diagnostic criteria for severe sud * admitted to the therapeutic community (tc) for full-length sud rehabilitation and with no more than 3 previous rehabilitation trials in this tc * abstained from drugs and alcohol for at least 14 days (verifying minimum withdrawal effects); and no more than 21 days of tc residency (to ensure familiarization with the facility) * without a significant cognitive deficit \[the montreal cognitive assessment (moca)≥19/30 points) and adequate language skills exclusion criteria: * relapsing substance use in the tc

Keywords: rehabilitation compliance executive functions sensory modulation dysfunction
to evaluate the efficacy and safety of hsk16149 capsule in chinese patients with postherpetic neuralgia

Conditions: Postherpetic Neuralgia

Summary: investigate the efficacy and safety of hsk16149 capsules in chinese postherpetic neuralgia following 12 weeks treatment in comparison to placebo


Eligibility criteria:
inclusion criteria: 1. signed informed consent; 2. males or females aged 18-75 years of age inclusive; 3. outpatient, patients can not stay in the hospital overnight; 4. patients must have pain present for more than 1 months after the healing of the herpes zoster skin rash; 5. at screening, pain scale (vas) of ≥40 mm; exclusion criteria: 1. peripheral neuropathy or pain unrelated to phn that may confuse the assessment of phn; 2. skin conditions in the area affected by neurupathy that could alter sensation; 3. chronic systemic diseases that may affect subjects' participation in the study; 4. severe hematologic, hepatic or renal dysfunction, the subject will be excluded if:1)neutrophils \ 2.5 × upper limit of normal (uln), or tbil \> 1.5 × uln, or 3)estimation of glomerular filtration rate (egfr) \ 2.0 × uln. 5. uncontrolled diabetes(hba1c≥11.0% at screening) ; 6. history of substance abuse or alcohol abuse; 7. any active infections at screening; 8. hbsag or hcv ab positive, or hiv ab positive, or serum tp ab positive; 9. inability or unwillingness to discontinue any other prohibited concomitant medications (see section 6.3); 10. patients who have undergone neurolytic or neurosurgical therapy 1 week before screening for postherpetic neuralgia; 11. failure to response to previous treatment with pregabalin at doses ≥ 300 mg/d or gabapentin at doses ≥ 1200 mg/d for treatment of phn; 12. history of allergic or medically significant adverse reaction to investigational products or their excipients, acetaminophen or related compounds; 13. history of suicidal behavior or attempted suicide; 14. pregnant or preparing for pregnancy or breastfeeding during the study period, or subjects were not willing to use reliable contraceptives methods from the date of icf signature until 28 days after the last trial drug administration, or planning to use progesterone contraceptives during this period; 15. mechanical operators who are engaged in high-altitude operations, motor vehicle driving and other dangerous machinery operators; 16. participated in another clinical study within 30 days prior to screening; 17. other conditions unlikely to participate in this trial.
neoadjuvant chemotherapy followed by radical hysterectomy (op) versus primary chemo-radiation in cervical cancer figo stage ib2 and iib

Conditions: Cervical Cancer

Summary: randomized comparison of neoadjuvant chemotherapy followed by radical hysterectomy with pelvic ± para-aortic lymphonodectomy (lne) versus primary cisplatin-based chemo-radiation in patients with cervical cancer figo ib2 and iib.

the optimal treatment for patients with cervical cancer on figo stage ib2 and iib is controversial. there is no randomized comparison of a dose-dense nact (tp or tip-schedule) followed by hysterectomy and lne (investigational arm a) versus primary chemo-radiation (standard arm b). primary endpoint is the dfs at 5 years, secondary endpoints local control at 5 years, os at 5 years, qol, questionnaires on sexual activity/qol.

Eligibility criteria:
inclusion criteria: * \>18 years * cervical cancer figo ib2, iib, * squamous cell, adeno or adenosquamous cell carcinoma * informed consent exclusion criteria: * small cell/neuroendocrine component * previous radiation, previous cancer * pregnancy * hiv * severe co-morbidities

Keywords: neoadjuvant chemotherapy figo ib2, figo iib chemo-radiation dose dense chemotherapy cisplatin paclitaxel carboplatin ifosfamide
characterization of proliferating compartment in b-cell patients and in healthy aging subjects

Conditions: Chronic Lymphocytic Leukemia

Summary: by ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the dna of newly developed cells in the body of subjects with b-cell chronic lymphocytic leukemia can be labeled and followed by performing routine blood draws at specified time intervals. by using mass spectrometric analysis we can measure how quickly new b-cll cells are generated in the bone marrow and how quickly they leave the blood, a measure of cell turnover. this will help us to better understand the unique characteristics of this disease process.

by ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the dna of newly developed cells in the body of subjects with b-cell chronic lymphocytic leukemia (b-cll) can be labeled and followed by performing routine blood draws at specified time intervals. by using mass spectrometric analysis we can measure how quickly new b-cll cells are generated in the bone marrow and how quickly they leave the blood, a measure of cell turnover. this will help us to better understand the unique characteristics of this disease process.

Eligibility criteria:
inclusion criteria: * 18 years of age, * patients must be willing to contribute the required amount of blood without compromising their well being, * participants must be willing to be contacted in the future. exclusion criteria: * pregnancy, * patients who are known to be anemic, with a hemoglobin \< 8, * patients who are known to be infected with hiv.

Keywords: chronic lymphocytic leukemia
study of a new generation botulinum toxin a2ntx to treat spasticity after stroke

Conditions: Lower Limb Spasticity After Stroke

Summary: to test the safety and efficacy of a new generation botulinum toxin preparation a2ntx for treating stroke patients with lower limb spasticity. * we study the degree of spasticity in the ankle and knee joints, and walking speed in 30 patients with stroke before and after injecting 300 units of botox or a2ntx in a blinded manner as for the patient, the physician, and the examiner. * we also assess the safety of a2ntx and compare it to that of botox.


Eligibility criteria:
inclusion criteria: * patients with lower limb spasticity after stroke * duration more than 6 months * modified ashworth scale of ankle joint more than 2 exclusion criteria: * patients with previous botulinum toxin injections to lower limbs * patients with serious hepatic, renal or cardiac dysfunction * patients with respiratory failure * patients who cannot understand the instructions

Keywords: poststroke spasticity lower limb botulinum toxin a2
the effect of epidural steroid use in patients with continous epidural block in phn patients.

Conditions: Neuralgia,Postherpetic

Summary: the efficiency of epidural steroid injection in patients who has postherpetic neuralgia is well known. in this study, the purpose is whether the continous epidural steroid injection is effective or not.

continous epidural injection will be done during 10 days. d group will be injected a 0.19% ropivacaine 8ml and dexametasone 1mg every other day during 10 days. continous epidural injection will be done during 10 days n group will be injected a 0.19% ropivacaine 8ml only every other day during 10 days

Eligibility criteria:
inclusion criteria: * patients who has herpes zoster * patients has a period (at least 1month) after onset of herpes zoster * patients has a definite symptom along dermatome * asa class i - ii * age : 18 - 80 years exclusion criteria: * patients who has a cancer * patients who has a neurologic, psychologic, renal, hepatic and hematologic disease * patients who has a other dermatologic disease * patients who has major operation \& procedure history * patients who has a other pain origin * patients who can not be inserted epidural catheter
a multicenter clinical trial of sputum dna testing for lung cancer in china

Conditions: Lung Cancer; Small Cell Lung Cancer; Non-Small Cell Lung Cancer; Squamous Cell Carcinoma; Adenocarcinoma; Large Cell Carcinoma; Adenosquamous Carcinoma; Sarcomatoid Carcinoma; Respiratory Tract Infection; Acute Bronchitis; Pneumonia; Chronic Bronchitis; Chronic Obstructive Pulmonary Disease; Tuberculosis; Lung Neoplasm; Pulmonary Interstitial Fibrosis

Summary: the primary objective of this study is to assess the safety and effectiveness of human multigene methylation detection kit (fluorescent pcr method) for help diagnose lung cancer by comparing with clinical standard method (includes chest ct examination or pathological examination).

in this clinical trial, the testing kit to be evaluated is a human multigene methylation detection kit (fluorescent pcr method), which is intended to qualitatively detect methylation levels of multiple genes in human sputum specimen in vitro by fluorescent pcr method, and the standard method used in clinical diagnosis is chest ct examination or pathological examination. subjects will provided sputum specimen as required for the evaluation of the testing kit followed by a chest ct examination or pathological examination. technical personnel who conduct the evaluation of the testing kit will remain blinded to the results of the clinical diagnosis by chest ct and/or pathological examination. the results of the testing kit will be compared with the standard method, and the effectiveness of the human multigene methylation detection kit (fluorescent pcr method) for lung cancer detection under normal clinical use will be assessed through statistical analysis.

Eligibility criteria:
inclusion criteria: * subject must meet all three of the following criteria to be eligible for the study: 1. no age or gender restrictions, voluntary participation and signing of informed consent form; 2. meet any of the following conditions: 1. suspected of lung cancer without invasive examination; 2. diagnosed with lung cancer without surgery, radiotherapy, chemotherapy, or targeted therapy; 3. diagnose other respiratory diseases, such as pulmonary infections (bacterial pneumonia, mycoplasma pneumonia, chlamydia pneumonia, viral pneumonia, lung abscess, etc.), interstitial lung diseases (pulmonary fibrosis, pulmonary granulomas, etc.), benign pulmonary nodules, tuberculosis, emphysema, pulmonary cysts, benign pulmonary tumors, obstructive pulmonary disease, bronchial infections/asthma, acute upper respiratory tract infections, etc; 4. diagnose other malignant tumors, such as thyroid cancer, esophageal cancer, liver cancer, gastric cancer, pancreatic cancer, etc. exclusion criteria: * any of the following conditions must be excluded: 1. patients who have undergone tracheotomy or have been on a ventilator due to severe illness. 2. the research physician believes that other reasons are not suitable for participants in this trial.

Keywords: lung cancer sputum dna test gene methylation biomarkers multigene methylation detection cancer screening
vr training for nurses' delirium management

Conditions: ICU Nurses, Delirium, Virtual Reality

Summary: background: delirium is an acute mental status change characterized by confusion, fluctuating symptoms, and inattention. it affects 11%-40% of hospitalized elderly patients and over 80% of mechanically ventilated icu patients. early detection and intervention are crucial in preventing adverse outcomes. the confusion assessment method for the icu (cam-icu) has been widely adopted in taiwan for delirium screening. however, nurses' knowledge and skills in delirium assessment remain insufficient. objective: this study aims to evaluate the effectiveness of a spherical video-based virtual reality (svvr) training system in improving nurses' delirium assessment and management skills. methods: a parallel-group randomized controlled trial will be conducted. participants (nurses aged 20-65) will be recruited via social media and screened for eligibility. they will be randomly assigned to: intervention group: svvr-based delirium training using a head-mounted display. control group: standard video-based training via youtube. pre- and post-intervention assessments will measure delirium knowledge, attitudes, assessment skills, learning motivation, and technology acceptance. quantitative data will be analyzed using spss (version 25) with t-tests, anova, and chi-square tests. qualitative data will be analyzed using thematic analysis. expected outcome: this study will determine whether immersive vr training enhances nurses' delirium management skills more effectively than conventional video training.


Eligibility criteria:
inclusion criteria: * aged between 20 and 65 years. * currently a licensed nurse and practicing. * willing to participate in this study and comply with the related procedures. * completed and signed the written informed consent form. exclusion criteria: * nurse managers or nurses who do not directly care for patients, or nurses working in outpatient or community settings. * individuals with epilepsy, heart disease, or dizziness. * individuals with anxiety, panic disorder, or claustrophobia. * individuals with myopia greater than 600 degrees or those who have previously undergone eye surgery.
does steroid plus co2 laser improve lichen sclerosus symptoms compared to steroids alone?

Conditions: Vulvar Lichen Sclerosus

Summary: this study will compare the effects of fractionated co2 laser plus topical steroids versus topical steroids alone in treatment of lichen sclerosus.

vulvar lichen sclerosus is a common benign skin condition which causes pain and itching. topical steroids have been the main treatment. a recent study showed that fractionated co2 laser treatment is non inferior and actually may improve subjective symptoms compared to topical steroids with no serious safety or adverse events. because steroids reduce risk of vulvar cancer in patients with lichen sclerosus, the investigators hypothesize that steroids in addition to the fractionated laser will provide greater symptom relief while still allowing patient the benefits of steroid treatment.

Eligibility criteria:
inclusion criteria: * women with biopsy proven lichen sclerosus and significant symptoms based on skindex-29 scores \>21 exclusion criteria: * prior vaginal mesh or pelvic radiation * active genital infection * current or past gynecologic malignancy

Keywords: monalisa touch fractionated laser smartxide2
follicular revival in androgenic alopecia: evaluating use of micro-needling

Conditions: Androgenic Alopecia

Summary: the intent of this study is to evaluate the efficacy of microneedling through use of a professional tattoo machine in hair regrowth in patients with androgenic alopecia (aga) over up to 6 treatments (6 months).

proposed is an open label trial of tattoo machine microneedling in ten patients with androgenic alopecia. ten healthy male patients older than 18 years will undergo 6 microneedling sessions. over the course of six months, subjects will undergo up to six treatment sessions (one session every 30 day). patients will be evaluated at 8 visits over 8 months with the first visit for screening purposes.

Eligibility criteria:
inclusion criteria: * symmetric hair loss from aga * hamilton-norwood iiia, iii, iii vertex, iv, iva, v with low density hair coverage over majority of alopecic areas * no or minimal scalp hair regrowth on oral and/or topical minoxidil exclusion criteria: * any male with hair loss for other reasons * unilateral or asymmetric hair loss * hamilton-norwood i, ii, iia, va, iv, vii x * patients without hair * patients with the following who would make poor candidates for microneedling such as skin conditions, diabetes, or history of keloid formation * anything additional existing comorbidities that in the opinion of the investigator may cause unnecessary risk for the patient to participate
mental health in adults and children- frugal innovations (mac-fi): adult depression component

Conditions: Depression

Summary: this stepped wedge, randomized controlled trial will test the effectiveness of a supported self-management intervention for depression among adults in vietnam. the intervention will be delivered at the community level in 8 vietnamese provinces by primary care providers and social workers. the intervention group will receive the supported self-management intervention, while the control group will receive enhanced treatment as usual. the primary outcome measure for depression is the self-reporting questionnaire-20 (srq-20). the world health organization's disability assessment scale (whodas 2.00 and the cage (concern/cut-down, anger, guilt, and eye-opener) measures are also used to assess functional ability and alcohol misuse.


Eligibility criteria:
inclusion criteria: * score of \>7 on srq-20 indicating depression caseness * consent to participate and complete all measures exclusion criteria: * cognitive disturbance * psychotic symptoms
dacron vs dardik for fem-pop bypass

Conditions: Intermittent Claudication; Arterial Occlusive Diseases; Atheroslerosis

Summary: clinical trial for the comparison of long-term patency of heparin-bonded dacron and human umbilical vein vascular prostheses in above-knee femoro-popliteal bypass surgery.


Eligibility criteria:
inclusion criteria: * age 31 to 89 * intermittent claudication * abi below 0.8 exclusion criteria: * non elective surgery * life expectancy below 2 yrs * contraindication for anticoagulant therapy
convalescent plasma in pediatric covid-19

Conditions: COVID

Summary: covid-19 is increasingly affecting children but convalescent plasma (cp) has not been adequately studied in children to date. the study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, covid-19 disease.

covid19 is an emerging infection with no current approved treatment or prevention. covid-19 is increasingly affecting children but convalescent plasma (cp) has not been adequately studied in children to date. the study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, covid-19 disease.

Eligibility criteria:
inclusion criteria: * aged 0 to 22 years of age * sars-cov-2 infection documented by rna rt-pcr detection * admitted to an acute care facility * ability of patient or guardian to provide consent and assent (if applicable); if patient is intubated assent may be waived exclusion criteria: * pregnancy/ breast feeding * medical condition that increases the risk of plasma infusion * contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products). inclusion criteria for infusion: * severe covid-19 disease, or * moderate disease with a risk of progression to severe or life threatening disease, or * severely immunocompromised patient with any illness attributed to covid-19 disease requiring inpatient care. exclusion to infusion: * pregnancy/ breast feeding * medical condition that increases the risk of plasma infusion * contraindication to transfusion (severe volume overload, history of anaphylaxis to blood products).

Keywords: covid-19 pediatric convalescent plasma safety